tbuckley/cabot-search huggingface dataset:
94P Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Authors: T. Kajiwara, T. Nishina, R. Yamashita, Y. Nakamura, M. Shiozawa, S. Yuki, H. Taniguchi, H. Hara, T. Ohta, T. Esaki, E. Shinozaki, A. Takashima, Y. Yamamoto, K. Yamazaki, T. Yoshino, I. Hyodo
Journal: Annals of Oncology (2023)
9P Clinicopathological features and prognosis of mucinous breast cancer: A retrospective analysis of 358 patients in Vietnam
Authors: H.T. Hoang, H. Phung Thi, L.T. Nguyen, T.V. Nguyen, T.H. Nguyen, A.T. Do, H.N. Nguyen, Q.H. Le, T. Nguyen Thanh
Journal: Annals of Oncology (2023)
420P Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Authors: X. Zhang, Y. Chen, W. Zhou, L. Gao, Z. Xie, J. Chen, Y. Huang, W. Yan, X. Yang, B-C. Wang, D. Lu, Z. Lv, W. Guo, S. Zhang, Y-L. Wu, J-J. Yang
Journal: Annals of Oncology (2023)
338P Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Authors: Y. Wei, W-X. Liu, F. Qi, C-G. Zhang, B-M. Zheng, Y. Xie, C. Bo, D. Zhang, W. Liu, H. Fang, Y. Chai, S. Qi, Y. Li, W-H. Wang, Y. Song, J. Zhu, M. Dong
Journal: Annals of Oncology (2023)
439P Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Authors: C. Wongkraisri, K. Chusuwanrak, A. Laocharoenkeat, L. Chularojmontri, A. Nimmannit, S. Ithimakin
Journal: Annals of Oncology (2023)
490MO Patient-reported outcomes of first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive advanced non-small cell lung cancer: Interim analysis of LIBRETTO-431
Authors: K. Goto, S. Novello, P. Garrido Lopez, C. Dooms, J.A. Alatorre Alexander, N. Reinmuth, A. Gilligan, N. Payakachat, A. Lin, K. Cocks, G. Worthy, C. Zhou
Journal: Annals of Oncology (2023)
555P Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Authors: J.C.S. Ho, C.H.L. Wong, K.S.J. Fong, V.H.F. Lee, M.Y. Lim, T.Y. Kam, S.F. Nyaw, C.K. Kwan, F. Mok, A.W.M. Lee, K.M. Cheung
Journal: Annals of Oncology (2023)
556P Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Authors: X. Hao, S. Zhang, Y. Hu, W. Zhuang, J. Fang, Y. Liu, M. Wang, M. Si, Y. Sang, X. Kang, Y-K. Shi
Journal: Annals of Oncology (2023)
405MO Pan-cancer analysis of 4-1BB transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors
Authors: Y. Uehara, S. Kato, D. Nishizaki, H. Miyashita, J.J. Adashek, S. Lee, M. Nikanjam, R.N. Eskander, H. Patel, G. Botta, M. Nesline, S. Pabla, J.M. Conroy, P. Depietro, J. Sicklick, R. Kurzrock
Journal: Annals of Oncology (2023)
417P Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Authors: S. Dawood, S.S. Jain, V. Lavingia, D. Aderka, E. Tahover, M. Temper, A. Goldman, M. Al Akasheh, S. Olsen, S. Hsing, N. Joshi
Journal: Annals of Oncology (2023)
545P Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Authors: A. Fantoni, L. Warburton, B. Solomon, M. Alexander, M. Maddula, I. Pires Da Silva, L.J. Brown, A. Nagrial, F. Abu Al-Hial, M. Itchins, N. Pavlakis, S.E. Bowyer
Journal: Annals of Oncology (2023)
470TiP Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Authors: P-J. Voon, T.L. King, X.Y. Lim, E.H-Y. Lau, N.B. Ishak, D.Z.F. Lee, S.P. Beh, S.H. Tan, S.S.N. Tan, L.L. Tiong, D.A. Mohamed Noor, K.H. Yuen
Journal: Annals of Oncology (2023)
LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis
Authors: S. Lu, B.C. Cho, J-S. Lee, S-H. Lee, P. Danchaivijitr, B. Liu, A. Alip, H. Xiong, S.H. How, G-C. Chang, J.C-H. Yang, H. Yoshioka, K. Xia, M. Martinez, J.M. Bauml, S. Sethi, H. Hayashi
Journal: Annals of Oncology (2023)
573P LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Authors: B.C. Cho, Q. Xu, S. Ng, J.W. Goldman, N. Girard, D. Planchard, S. Baijal, R. Kamalakar, V. Blot, H. Alhasani, S. Karve, S. Lu
Journal: Annals of Oncology (2023)
441P The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Authors: Y-K. Shi, Q. Zhang, X. Wang, Z. Pei, J. Wang, T. Yi, Z. Ouyang, J. Mei, H. Shi, T. Sun, Y. Zhang, J. Bai, T. Ma, S. Cang, Y. Guo, Y. Li, G. Fu, Y. Dong, S. Zhou, L. Sun
Journal: Annals of Oncology (2023)
599TiP A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Authors: S. Zhan, J. Li, B. Cheng, J. He, W. Liang
Journal: Annals of Oncology (2023)
482P Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Authors: P.L. Chia, J.T. Kit Chung, A. Asmat, R. Huggenberger, A. Verma, R.A. Soo
Journal: Annals of Oncology (2023)
LBA9 Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)
Authors: S. Lu, Y. Zhang, G. Zhang, J. Zhou, S. Cang, Y. Cheng, G. Wu, P. Cao, D. Lv, H. Jian, C. Chen, X. Jin, P. Tian, K. Wang, G. Jiang, G. Chen, Q. Chen, H. Zhao, C. Ding, L. Ding
Journal: Annals of Oncology (2023)
360MO Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study
Authors: L. Gui, X. Chen, X. He, J. Yang, P. Liu, Y. Qin, Y-K. Shi
Journal: Annals of Oncology (2023)
515MO Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates
Authors: H. Horinouchi, B.C. Cho, D.R. Camidge, K. Goto, P. Tomasini, Y. Li, A. Vasilopoulos, P. Brunsdon, D. Hoffman, W. Shi, V. Blot, J.W. Goldman
Journal: Annals of Oncology (2023)
511MO A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced non-small cell lung cancer (NSCLC)
Authors: J. Feng, M. Shi, J. Chen, K. Li, X. Li, M. Sun, B. Li, G. Wen, Y. Fang, X. Min, L. Lin, Y. Liu, Q. Wang, S. Lu, B. Zhu, Y-K. Shi, H. Yu, Y. Peng, F. Liang, P. Liu
Journal: Annals of Oncology (2023)
401TiP Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Authors: R. Lin, L. He, M. Lu, Y. Wang, J. Liu, Q. Li, X. Lu, L. Zhuang, Z. Zhang, L. Gong, Y. Luo, L. Cao, J. Zhong, H. Zou, T. Ren, C. Shang, S. Lin, S. Zhao, L. Su, C. Huang
Journal: Annals of Oncology (2023)
508MO Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study
Authors: L. Paz-Ares, M-J. Ahn, E. Felip, S. Handzhiev, I. Korantzis, H. Izumi, K. Ohashi, M. Majem Tarruella, J. Wolf, M. Reck, H-D. Hummel, F. Blackhall, A-M.C. Dingemans, T.K. Owonikoko, S.S. Ramalingam, J. Sands, T. Jiang, S. Mukherjee, E. Anderson, B.C. Cho
Journal: Annals of Oncology (2023)
313P Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Authors: R. Ghosh, P. Biswas, K. Mukherjee, R. Mandal, M. Vernekar, P. Chatterjee, T. Maji, D. Lahiri, B. Dutta, S. Mazumder, J. Chakrabarti
Journal: Annals of Oncology (2023)
585P Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Authors: T.S.K. Mok, G. Liu, S.F. Nyaw, H. Curcio, A. Cortot, T.Y. Kam, R. Descourt, Y.K. Chik, P.K. Cheema, J.M. Gwinnutt, E.N. Churchill, J. Nyborn, E. Curran, Y. Yin, K. Chong, Y. Tanaka-Chambers, J. Kretz, J. Cadranel
Journal: Annals of Oncology (2023)
560P Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Authors: C. Weng, K. Tang, S. Jin, C. Zhou, Y. Yao, J-W. Su, H. Chen, K. Liu, Y. Li, J. Yang
Journal: Annals of Oncology (2023)
445P Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Authors: V.C.W. Tam, J.C.F. Ching, S.S.T. Yip, V.H.Y. Kwong, C.P.L. Chan, K.C.W. Wong, S.W.Y. Lee
Journal: Annals of Oncology (2023)
294P Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Authors: L.T. Nguyen, M.V. Dang, C.V. Nguyen, N.D.T. Thanh, V.A.T. Dang, H. Khuc Chi, A.D. To, H. Phung Thi
Journal: Annals of Oncology (2023)
415P Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Authors: S. Tucker, M. Pek, C. Hao, Z.Y. Wan, K.C. Ngeow, J. Poh, M. Lim, D. Poon, M-H. Tan
Journal: Annals of Oncology (2023)
335MO Real-world outcomes of diffuse large B cell lymphoma treated with R-CHOP(-like) therapy in an Asian multi-ethnic population
Authors: J.C.Y. Sheng, Z.E.Q. Heng, J.Y. Tan, Y.H. Tan, E.W.Y. Chang, J.T.M. Hoe, V.S. Yang, J. Chiang, E.Y.L. Poon, N. Somasundaram, M.F. Harunal Rashid, J.Q. Lim, C.K. Ong, L.C.K. Ng, F.L.W.I. Lim, M. Tao, Y.T. Goh, S.T. Lim
Journal: Annals of Oncology (2023)
499P Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Authors: D. Fujimoto, Y. Takiguchi, S. Matsumoto, N. Yamamoto, G. Saito, Y. Nishimura, S. Sugiyama, A. Oku, P. Karia, L. Antunes, J. Chapaneri, R.J-B. Salomonsen, E. Martin, P. Okhuoya, M. Muto
Journal: Annals of Oncology (2023)
513MO Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis
Authors: C. Zhou, K. Tang, B. Liu, S-W. Kim, S. Kitazono, A. Ono, M. Thiagarajan, J-Y. Hung, M. Boyer, J. Xie, A. Bhattacharya, M. Baig, T. Agrawal, R.E. Knoblauch, B.C. Cho
Journal: Annals of Oncology (2023)
600TiP Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Authors: J. Tanizaki, H. Akamatsu, J. Su, G-W. Lee, M.S. Xia, B. Ainsworth, M. Li, E. Bolotin, J. Seraj, S. Lu
Journal: Annals of Oncology (2023)
516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
Authors: F. Cappuzzo, V. Moreno Garcia, S-H.I. Ou, M. Brandão, M.F. Sanmamed, C. Helissey, M. Wislez, J.A. Call, S. Grisanti, M.L. Johnson, V. Boni, P. Jamme, I. Monnet, S. Siena, C. Yan, B. Barasa, B. Richard, A.K. Joe, G. Laus, E. Felip
Journal: Annals of Oncology (2023)
580P Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Authors: S. Wang, Y. Wang, L. Wang, Y. Liu, Y. Hu, Z. Liu, Y. Yao, L. Liang, J. Liu, J. Li, P. Xing
Journal: Annals of Oncology (2023)
500P The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Authors: H. Horinouchi, M. Furuta, I. Yokota, T. Yamaguchi, S. Itoh, T. Fukui, A. Iwashima, Y. Kawashima, Y. Miura, H. Tanaka, T. Miyawaki, H. Yokouchi, K. Miura, R. Saito, H. Suzuki, T. Kamoshida, U. Uchinami, T. Kato, K. Kobayashi, H. Asahina
Journal: Annals of Oncology (2023)
291MO Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial
Authors: J. Li, M. Wu, Z. Lin, Y. Lai, B. Zhang, Y-F. Ye, Y. Lu, Y. Peng
Journal: Annals of Oncology (2023)
546P Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Authors: T. Minami, A. Tada, H. Kitai, T. Fujioka, N. Kawamura, T. Kondo, M. Murakami, M. Morishita, M. Tokuda, T. Higashiyama, Y. Negi, D. Horio, T. Otsuki, K. Mikami, R. Takahashi, K. Kuribayashi, T. Kijima
Journal: Annals of Oncology (2023)
451P The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Authors: D. Arai, R. Kido, J. Yamaguchi, S. Kamimoto, S. Furuya, A. Kanzawa, M. Miyazaki, R. Baba, S. Okamori, H. Takahashi, I. Nakachi
Journal: Annals of Oncology (2023)
362P Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
Authors: P. Bossi, G. Minuti, I. Braña, V. Moreno Garcia, V. Boni, P. Jamme, J.A. Call, C. Yan, B. Barasa, P. Doze, A.K. Joe, G. Laus, A. Daste
Journal: Annals of Oncology (2023)
521P Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Authors: Y. Zhao, J. Liu, X. Li, Y. Li, H. Pu, X. Wang, M. Yang, S. Bai, L. Guo, L. Zhao, M. Zhang, H. Zhao, S. Xu, Y. Wang
Journal: Annals of Oncology (2023)
486P Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Authors: H.H.F. Loong, X. Pan, C.H. Chiu, S-C. Yang, M.S-H. Chung, L. de Jong, H.J.M. Groen, M. Oudkerk, M.J. Postma, C.K.H. Wong, P-C. Yang
Journal: Annals of Oncology (2023)
509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
Authors: M-J. Ahn, A.E. Lisberg, L. Paz-Ares, R. Cornelissen, N. Girard, E. Pons-Tostivint, D. Vicente Baz, S. Sugawara, M. Cobo Dols, M. Pérol, C. Mascaux, E. Poddubskaya, S. Kitazono, H. Hayashi, J. Sands, R. Hall, Y. Zhang, H. Zebger-Gong, D. Uema, I. Okamoto
Journal: Annals of Oncology (2023)
507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC
Authors: P.A. Jänne, B-C. Wang, B.C. Cho, J. Zhao, J. Li, M.J. Hochmair, S. Peters, B. Besse, T. Kato, Y-L. Wu, D. Nguyen, J. Lin, J. Lin, F. Vranceanu, M. Lin, R.J. Fram, T.S.K. Mok
Journal: Annals of Oncology (2023)
471TiP A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Authors: M.K. Ramasubbu, D. Hota, S.K.K. Das Majumdar, P. Mukherjee, A. Srinivasan
Journal: Annals of Oncology (2023)
363P Effect of financial distress and mental well-being of patients with early vs advanced oral cancer on informal caregiver's quality of life: A prospective real-world data from public health sector hospital
Authors: A. Thaduri, K. Majumdar, A. Panuganti, S. Usmani, D. Dungala, V. Kailey, M. Malhotra
Journal: Annals of Oncology (2023)
567P Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Authors: F.S. Cun, M. Zhao, X. Wang, T. Xu
Journal: Annals of Oncology (2023)
505P Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Authors: J. Hu, F. Sun, D. Bian, J. Yang, J. Luo, G. Jiang, Y. Zhu, P. Zhang
Journal: Annals of Oncology (2023)
337P Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Authors: X.Y. Lim, H. Hasan, F. Rafiee, J. Ha, L.P. Khoo, A.N.H. Sairi, S.T. Lim, J.C.Y. Sheng
Journal: Annals of Oncology (2023)
330MO Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies
Authors: J. Zhu, J. Li, C.S. Tam, H. Guo, L. Wang, H. Zhou, M. Zhang, J. Zhang, A. Cohen, N. Bahadur, P. Khanna, W.S. Kim, L. Qiu
Journal: Annals of Oncology (2023)
354O A phase Ib/II study of nanatinostat (Nstat) plus valganciclovir (VGCV) in EBV+ solid tumors and with pembrolizumab (PEM) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)
Authors: A.D. Colevas, L. Siu, D.W-T. Lim, B. Gao, P-J. Voon, S. Khan, L. Eng, M-J. Ahn, V. Lee, H.M. Wang, M-H. Yang, D. Bowles, R. Ferrarotto, A. Elguindy, A. Katkov, K. McGovern, B. Ma
Journal: Annals of Oncology (2023)
561P Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Authors: D. Harada, A. Tamiya, M. Osuga, Y. Mizumori, S-I. Isa, Y. Taniguchi, K. Nakamura, T. Shinohara, H. Yanai, K. Nakatomi, M. Oki, M. Mori, T. Kuwako, K. Yamazaki, A. Tamura, M. Ando, Y. Koh
Journal: Annals of Oncology (2023)
424P MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Authors: B.B.Y. Ma, A. Johnson, K.R. Mills Shaw, H.H.F. Loong, F. Mo, R.N. Lui, K.H. Wong, Z. Zeng, V. Holla, M. Kahle, T. Vu, F. Su, S-H. Kim, T. Conway, Q. Wang, W. Tao, L. Zhou, J. Rodon, F. Meric-Bernstam, T.A. Yap
Journal: Annals of Oncology (2023)
562P First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Authors: Y. Cheng, Y. Yu, Y. Fan, L. Jiang, L. Wu, J. Hu, J. Wang, W. Yao, Z. Han, Y. Yao, J. Fang, M. Sun, Q. Wang, Y. Pan, R. Wu, J. Liu, Y. Liu, D. Kulkarni, X. Huang, P.A. Jänne
Journal: Annals of Oncology (2023)
473P Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Authors: H. Wang, S. Lu, Y. Zhao, Y. Li, G. Hu, Y-C. Lee, C-C. Yang, A. Yin, Q. Wang, S. Tan, M. Sandelin, D. Kahangire
Journal: Annals of Oncology (2023)
358MO Quality-adjusted life-year and life-year estimates for patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the combined positive score 1-19 subgroup treated with pembrolizumab +/- chemotherapy vs cetuximab-containing regimens
Authors: P. Ivanyi, A. Bullement, M. Schlichting, J. Naik, C.P. Pescott
Journal: Annals of Oncology (2023)
402O A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary
Authors: Z. Luo, X. Liu, X. Zhang, S. Jiang, M. Mo, Q. Wang, Y. Wang, L. Zhou, S. Hu, H. Yang, Y. Hou, Y. Chen, X. Lu, X. Zhou, W. Li, X. Yang, K. Chen, J. Cao, Q. Xu, X. Hu
Journal: Annals of Oncology (2023)
428P What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Authors: F.A. Agatha, F. Ng, F. Aldila, J. Audrienna, L. Lim, S. Tang, S.G. Tanu, E. Fernandez, M. Wijaya, S. Sormin, L. Sani, A. Irwanto, S.J. Haryono, A. Chan, J. Li, M. Hartman
Journal: Annals of Oncology (2023)
438P A novel treatment for immune checkpoint inhibitor-related myocarditis
Authors: T. Niimura, K. Uchida, H. Unten, M. Uno, M. Kanamori, H. Hamano, M. Goda, K. Yagi, F. Aizawa, Y. Izawa-Ishizawa, Y. Zamami, K. Ishizawa
Journal: Annals of Oncology (2023)
449P Psychometric validation of the MD Anderson symptom inventory head&amp;neck module: Chinese version in nasopharyngeal cancer survivors
Authors: S.W.Y. Lee, V.C.W. Tam, J.C.F. Ching, S.S.T. Yip, V.H.Y. Kwong, C.P.L. Chan, K.C.W. Wong
Journal: Annals of Oncology (2023)
433MO Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: A multi-center study
Authors: Q. Liu, M. Liu, Z. Zou, J. Lin, Y. Wang, N. Zhang, L. Zhao, J. Zhou, H. Zhou, X. Zhou, X. Jiao, Y. Yu, T. Liu
Journal: Annals of Oncology (2023)
532P The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Authors: T. Otsuki, N. Kawamura, M. Murakami, T. Kondo, T. Fujioka, M. Morishita, M. Tokuda, T. Higashiyama, A. Tada, Y. Negi, D. Horio, K. Mikami, R. Takahashi, T. Minami, K. Kuribayashi, T. Kijima
Journal: Annals of Oncology (2023)
484P Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Authors: M-J. Ahn, J.H. Kang, S-W. Kim, D. Kahangire, S.P. Nagar, K.L. Davis, M. Jimenez, M. Seo, M. Jung, M. Sandelin, B.C. Cho
Journal: Annals of Oncology (2023)
553P Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Authors: Q. Du, T.Y. Kam, F. Hioe, Y.H. Lui, W.L. Tang, C.Y. Wong, K.S. Wong, K.W. Ng, M.W. Yeung
Journal: Annals of Oncology (2023)
540P Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Authors: C. Zhou, Y. Hu, K. Ying, F. Xu, L. Wu, X. Wang, H. Sun, F. Luo, J. Shi, A. Zang, Y. Pan, Z. Chen, Z. Jia, P. Lu, L. Zhang, Y. Cheng, W. Kang, Q. Wang, J. Li, J. Zhu
Journal: Annals of Oncology (2023)
526P Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Authors: M.H. Chhayani, S.J. Obulareddy, S.K. Yadav, M. Khealani, M. Gaddam, S.M. Jain, H.D. Chhayani, H.D. Desai
Journal: Annals of Oncology (2023)
597TiP A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Authors: S.M. Lim, B.C. Cho, J-Y. Han, S-W. Kim, K.H. Lee, M. Nagasaka, T.R. Baisamut, A. Jo, E. Seah, C. Kim, S-H.I. Ou
Journal: Annals of Oncology (2023)
578P Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Authors: L-J. Hung, J.W-C. Chang, C-Y. Huang, Y-F. Fang, C-F. Chang, C-H.S. Kuo, P-C. Hsu, Y. Cheng-Ta, C-E. Wu
Journal: Annals of Oncology (2023)
316P First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Authors: J. Li, C. Youguo, H. Mian, X. Chen, H. Wen, Y. Kang, K.J. Liu, G. Lou, X. Wang, Q.L. Wen, L. Wang, Z. Lin
Journal: Annals of Oncology (2023)